deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03078478

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Sponsor: Novo Nordisk A/S

Conditions Diabetes Diabetes Mellitus, Type 2
Interventions Insulin degludec Insulin glargine
Updated 25 times since 2017 Last updated: Jan 6, 2022 Started: Mar 13, 2017 Primary completion: Feb 13, 2019 Completion: Mar 4, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetes and Diabetes Mellitus, Type 2, this trial is completed. The trial is conducted by Novo Nordisk A/S and has accumulated 25 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Apr 2017 – ~May 2017 · 30 days · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Jan 2019 · 5 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Mar 2019 · 28 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Feb 2022 · 12 months · monthly snapshot~Feb 2022 – ~Jul 2024 · 29 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

25 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Feb 2022 — Jul 2024 [monthly]

    Completed PHASE3

  5. Feb 2021 — Feb 2022 [monthly]

    Completed PHASE3

▶ Show 20 earlier versions

  1. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE3

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Oct 2019 — Apr 2020 [monthly]

    Completed PHASE3

  4. Jun 2019 — Oct 2019 [monthly]

    Completed PHASE3

  5. Apr 2019 — Jun 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  6. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Feb 2019 — Mar 2019 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE3

  9. Aug 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE3

  10. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

  14. Nov 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  15. Oct 2017 — Nov 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  16. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  17. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  18. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  19. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  20. Apr 2017 — May 2017 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novo Nordisk A/S
Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus N, Denmark , Albany, United States , Albuquerque, United States , Amarillo, United States , Anderson, United States , Anniston, United States , Arlington, United States , Athens, Greece , Austin, United States , Bad Mergentheim, Germany and 184 more locations